Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Johnson & Johnson announced that its Tecvayli® combined with Darzalex Faspro® treatment regimen has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma patients.

Johnson & Johnson announced that its Tecvayli® combined with Darzalex Faspro® treatment regimen has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma patients.

老虎证券老虎证券2026/03/05 21:03
Show original
This approval is significant because it provides patients with a potentially new standard of care, which can even be used early in the second-line treatment stage of the disease.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!